Evidence Hub

Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer’s disease: a population-based cohort study

L. Fardet, I. Nazareth, I. Petersen

Annals of the Rheumatic Diseases, 2018

12 participants · 17 citations

Abstract

Autophagy is an intracellular pathway by which cells generate energy and metabolites by recycling their own non-essential, redundant or damaged components.1 Pathophysiological studies have demonstrated that the impairment of autophagy contributes to protein aggregate accumulation that occurs during Alzheimer’s disease and experiments have shown that autophagy inhibitors, such as chloroquine and hydroxychloroquine, block amyloid plaque degradation.1 2 Further, a recent case–control study found that patients with rheumatoid arthritis who used hydroxychloroquine were at increased risk of dementia.3 We investigated whether chronic exposure to chloroquine/hydroxychloroquine increases the risk of Alzheimer’s disease.

Data from The Health Improvement Network (THIN) were used (January 1990–December 2016). THIN is a UK primary care database on >12 million people. Participating general practitioners prospectively enter clinical information on individuals so that the database provides a longitudinal medical record for each individual. THIN is representative of the UK population. …

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 12 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free